The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1494
BioThrax and Anthrasil for Anthrax
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved anthrax vaccine adsorbed (AVA; BioThrax – Emergent BioSolutions) for prevention of anthrax disease in adults following exposure to Bacillus anthracis and intravenous anthrax immune globulin (Anthrasil – Emergent BioSolutions) for treatment of inhalation anthrax in adults and children. AVA has been available since 1970 for prevention of anthrax disease in persons at high risk of exposure.

STANDARD TREATMENT — Management of a known or suspected inhalation exposure to anthrax in adults includes administration of three 0.5-mL subcutaneous injections of AVA at 2-week intervals and 60 days' treatment with an appropriate oral antibiotic such as ciprofloxacin or doxycycline.1,2 Raxibacumab, an intravenous human monoclonal antibody available only from the CDC, can be used for treatment of inhalation anthrax in combination with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: BioThrax and Anthrasil for Anthrax
Article code: 1494d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian